Latest Product Development News

Epiminder Limited has settled a $15.77 million tax liability with the ATO related to historical R&D claims, freeing up $4.23 million from IPO proceeds for working capital.

HITIQ Limited has successfully completed the initial tranche of a $900,000 placement, issuing over 40 million shares with attached options, while director participation awaits shareholder approval.

Biome Australia has initiated its first human clinical trial for the proprietary probiotic strain Lactobacillus plantarum BMB18, aiming to validate its benefits for digestive and mood-related symptoms.

Echo IQ has formally lodged its FDA 510(k) submission for EchoSolv HF, an AI-driven heart failure diagnostic software validated by Mayo Clinic data, aiming to tap into a $60 billion US market.

ABx Group has secured a new five-year exploration licence in northern Tasmania, expanding its rare earths tenure between key deposits and advancing its high-value rare earth product development.

HITIQ has secured a prestigious grant from the Australian Sports Commission to enhance its PROTEQT™ brain health monitoring technology, positioning the company for wider adoption across elite and community sports.

Dexus launches the Dexus Strategic Investment Trust series, acquiring a 25% stake in Westfield Chermside and raising $390 million for its DREP2 fund, while legal mediation is pushed to March 2026.

Spenda Limited has successfully raised $1.4 million through a private placement, attracting both new and existing sophisticated investors to support its product development and working capital needs.

Wisr Limited has successfully closed its Share Purchase Plan, raising $1.22 million and reducing corporate debt by $7.5 million as part of a broader $10.6 million capital raise.

Premier Investments reported a robust FY25 with a 31% rise in net profit, driven by strong performances from Peter Alexander and Smiggle, alongside a strategic capital return plan including a $100 million share buyback.

Identitii Limited has announced a pro rata non-renounceable rights issue to raise approximately $2.88 million, partially underwritten by Beauvais Capital Pty Ltd. The funds will support the development and commercialisation of its BNDRY platform amid ongoing patent litigation risks.

Anteris Technologies has secured regulatory green lights for its pivotal PARADIGM trial and raised $25.2 million in capital, advancing its innovative DurAVR® transcatheter heart valve towards commercialisation.